Commons, Marty

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

PDR001 Plus LAG525 for Patients With Advanced Solid and Hematologic Malignancies

Phase 2

Completed

Conditions: Ovarian Adenocarcinoma
Castration Resistant Prostate Adenocarcinoma
Advanced Well-differentiated Neuroendocrine Tumors
Gastric Adenocarcinoma
Small Cell Lung Cancer
Soft Tissue Sarcoma
Diffuse Large B Cell Lymphoma
Esophageal Adenocarcinoma

Interventions: Biological: PDR001
Biological: LAG525

First Posted Date: 2017-12-07

Last Posted Date: 2022-05-27

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 76

Registration Number: NCT03365791

Locations: 🇺🇸
Northwestern University Medical School, Chicago, Illinois, United States
🇺🇸
University of Illinois Cancer Center at Chicago SC, Chicago, Illinois, United States
🇺🇸
Oncology Consultants Oncology Consultants, Houston, Texas, United States

and more 17 locations

First-in-human, Safety, Tolerability and Pharmacokinetics Study of LRX712 in Osteoarthritic Patients

Phase 1

Completed

Conditions: Patients With Moderate Knee Osteoarthritis (30 - 65 Years)

Interventions: Drug: Placebo
Drug: LRX712

First Posted Date: 2017-11-28

Last Posted Date: 2020-12-11

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 42

Registration Number: NCT03355196

Locations: 🇳🇱
Novartis Investigative Site, Leiden, Netherlands

LYS228 PK, Clinical Response, Safety and Tolerability in Patients With Complicated Intra-abdominal Infection (cIAI)

Phase 2

Terminated

Conditions: Intra-abdominal Infections

Interventions: Drug: Standard of care therapy
Drug: LYS228

First Posted Date: 2017-11-28

Last Posted Date: 2021-10-11

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 3

Registration Number: NCT03354754

Locations: 🇺🇸
Novartis Investigative Site, Somers Point, New Jersey, United States

Study Estimating the Clinical Difference Between 300 mg and 150 mg of Secukinumab Following Dose Escalation to 300 mg in Patients With Ankylosing Spondylitis

Phase 4

Completed

Conditions: Ankylosing Spondylitis

Interventions: Drug: 150 mg open-label secukinumab
Drug: 150 mg double-blinded secukinumab
Drug: 300 mg double-blinded secukinumab

First Posted Date: 2017-11-22

Last Posted Date: 2022-04-29

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 322

Registration Number: NCT03350815

Locations: 🇺🇸
Novartis Investigative Site, Onalaska, Wisconsin, United States

Study of Efficacy, Safety and Tolerability of AIN457 in Patients With Active Overuse Tendinopathy

Phase 2

Completed

Conditions: Tendinopathy

Interventions: Other: Placebo
Drug: secukinumab

First Posted Date: 2017-11-17

Last Posted Date: 2021-10-08

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 96

Registration Number: NCT03344640

Locations: 🇬🇧
Novartis Investigative Site, Glasgow, United Kingdom

Dabrafenib and/or Trametinib Rollover Study

Phase 4

Recruiting

Conditions: Melanoma
Non Small Cell Lung Cancer
Solid Tumor
Rare Cancers
High Grade Glioma

Interventions: Drug: dabrafenib
Drug: trametinib

First Posted Date: 2017-11-13

Last Posted Date: 2025-04-06

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 100

Registration Number: NCT03340506

Locations: 🇺🇸
Honor Health Research Institute, Scottsdale, Arizona, United States
🇺🇸
National Institute Of Health, Bethesda, Maryland, United States
🇺🇸
James Cancer Hospital and Solove Research Institute Ohio State, Columbus, Ohio, United States

and more 2 locations

Efficacy, Safety and Tolerability of BAF312 Compared to Placebo in Patients With Intracerebral Hemorrhage (ICH).

Phase 2

Completed

Conditions: Hemorrhagic Stroke
Intracerebral Hemorrhage (ICH)

Interventions: Drug: BAF312 solution
Drug: Matching Placebo for BAF312 solution
Drug: Matching Placebo for BAF312 tablet
Drug: BAF312 tablet

First Posted Date: 2017-11-09

Last Posted Date: 2022-08-12

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 32

Registration Number: NCT03338998

Locations: 🇺🇸
Novartis Investigative Site, Charlottesville, Virginia, United States

Safety of KAE609 in Adults With Uncomplicated Plasmodium Falciparum Malaria.

Phase 2

Completed

Conditions: Malaria

Interventions: Drug: KAE609
Drug: Coartem

First Posted Date: 2017-11-07

Last Posted Date: 2021-10-11

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 188

Registration Number: NCT03334747

Locations: 🇺🇬
Novartis Investigative Site, Tororo, Uganda

Study on Safety, Tolerability and Prelimenary Efficacy of LNA043 in Patients Undergoing Autologous Chondrocyte Implantation

Phase 2

Terminated

Conditions: Knee Cartilage Lesion

Interventions: Biological: LNA043
Biological: placebo to LNA043

First Posted Date: 2017-11-07

Last Posted Date: 2021-10-07

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 14

Registration Number: NCT03334812

Locations: 🇦🇹
Novartis Investigative Site, Wien, Austria

Safety, Tolerability, and Efficacy Study of CLL442 in Patients With Cutaneous Squamous Cell Carcinoma in Situ (SCCis)

Phase 1

Terminated

Conditions: Cutaneous Squamous Cell Carcinoma in Situ (CSCCis)

Interventions: Drug: Placebo Cutaneous Cream application
Drug: Cutaneous Cream application

First Posted Date: 2017-11-07

Last Posted Date: 2020-12-11

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 40

Registration Number: NCT03333694

Locations: 🇧🇪
Novartis Investigative Site, Liege, Belgium

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy